ID   ABC-17
AC   CVCL_A1EG
DR   cancercelllines; CVCL_A1EG
DR   Cosmic; 2843084
DR   Wikidata; Q102113499
RX   PubMed=31374369;
CC   Population: Japanese.
CC   Characteristics: Established from a xenograft produced by subcutaneous injection of tumor cells into NOG (NOD/Shi-scid, IL-2RgammaKO Jic) mice.
CC   Characteristics: Resistant to alectinib and crizotinib.
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (PubMed=31374369).
CC   Sequence variation: Mutation; HGNC; HGNC:427; ALK; Simple; p.Gly1202Arg (c.3604G>A); ClinVar=VCV000376134; Zygosity=Unspecified (PubMed=31374369).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1EF ! ABC-14
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-04-25; Version: 8
//
RX   PubMed=31374369; DOI=10.1016/j.jtho.2019.07.017;
RA   Makimoto G., Ohashi K., Tomida S., Nishii K., Matsubara T.,
RA   Kayatani H., Higo H., Ninomiya K., Sato A., Watanabe H., Kano H.,
RA   Ninomiya T., Kubo T., Rai K., Ichihara E., Hotta K., Tabata M.,
RA   Toyooka S., Takata M., Maeda Y., Kiura K.;
RT   "Rapid acquisition of alectinib resistance in ALK-positive lung cancer
RT   with high tumor mutation burden.";
RL   J. Thorac. Oncol. 14:2009-2018(2019).
//